Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Acute deep vein thrombosis (DVT) of the leg involving proximal veins, and/or pulmonary embolism (PE) iin patients for whom at least 6 months of anticoagulant therapy is considered appropriate~2. Male or female, being 18 years of age or older~3. Written informed consent for study participation~Exclusion criteria~1. Overt symptoms of VTE for longer than 2 weeks prior to enrolment~2. PE satisfying at least one of the following criteria: Haemodynamic instability, embolectomy is indicated or performed, thrombolytic therapy is indicated or performed, or suspected source of PE is other than the legs~3. Actual or anticipated use of vena cava filter~4. Contraindications to anticoagulant therapy~5. Patients who in the investigators opinion should not be treated with warfarin~6. Allergy to heparins or other alternate approved therapy used for initial treatment, warfarin or dabigatran, or to one of the excipients included in these medications~7. Patients who in the investigators judgement are perceived as having an excessive risk of bleeding~8. Known anaemia~9. Need of anticoagulant treatment for disorders other than VTE~10. Recent unstable cardiovascular disease~11. Elevated AST or ALT \> 2x ULN~12. Liver disease expected to have any potential impact on survival~13. Patients who have developed transaminase elevations upon exposure to ximelagatran~14. Severe renal impairment~15. Women who are pregnant, nursing, or of childbearing potential who refuse to use a medically acceptable form of contraception~16. Participation in another clinical trial with an investigational drug during the last 30 days or previous participation in this study~17. Patients considered unsuitable for inclusion by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran etexilate 150 mg (Type: EXPERIMENTAL): twice daily
- warfarin (INR 2-3) (Type: ACTIVE_COMPARATOR): prn to maintain INR (2-3)

Based on this trial design, predict the completion outcome and termination type (if applicable).